Abstract
Detrusor Overactivity with Detrusor underactivity (formerly known as detrusor hyperactivity with impaired contractility) can often represent a diagnostic and therapeutic conundrum for urologists. Patients can present with a combination of symptoms, and the diagnosis is highly dependent on urodynamics, which can be difficult in the elderly population typically effected by DODU. This review gives an overview of our current knowledge of this disease. We will highlight the most recent literature regarding the therapies available for DODU. This includes use of mirabegron or third line therapy options such as OnabotulinumtoxinA and neuromodulation. We will additionally share some representative cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. JAMA. 1987;257(22):3076.
Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl. 1988;114:5–19.
Wein A, Kavoussi L, Partin A, Peters C, editors. Campbell-Walsh urology. 11th ed. Elsevier Inc.; 2016. p.1170–99, 1260–90.
Zhu Q, Ritchie J, Marouf N, Dion SB, Resnick NM, Elbadawi A, et al. Role of ovarian hormones in the pathogenesis of impaired detrusor contractility: evidence in ovariectomized rodents. J Urol. 2001;166(3):1136–41.
Griffiths DJ, McCracken PN, Harrison GM, Ann Gormley E, Moore KN. Urge incontinence and impaired detrusor contractility in the elderly. Neurourol Urodyn. 2002;21(2):126–31.
Smith AL, Kim J-H, Staack A, Baxter C, Rodriguez LV, Raz S. Urodynamic trends in the female aging population: detrusor hyperactivity with impaired contractility, two conditions or one? J Urol. 2009;181(4):598–9.
Chancellor MB. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014;46(Suppl 1):S23–7.
Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007;69(3):436–40.
Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn. 2006;25:356–60.
Yoshikawa S, Yoshizawa T, Takahashi R, Oguchi T, Yoshimura N. 1950 Voiding dysfunction with detrusor hyperactivity in pelvic nerve injured rats. J Urol. 2013;189(4S).
Resnick NM, Brandeis GH, Baumann MM, DuBeau CE, Yalla SV. Misdiagnosis of urinary incontinence in nursing home women: prevalence and a proposed solution. Neurourol Urodyn. 1996;15(6):599–618.
Valentini FA, Robain G, Marti BG, Nelson PP. Urodynamics in a community-dwelling population of females 80 years or older. Which motive? Which diagnosis? Int Braz J Urol. 2010;36(2):218–24.
Peterson AC, Fraser MO. Practical urodynamics for the clinician. Cham: Springer; 2016.
Osman N, Mangera A, Hillary C, Inman R, Chapple C. The underactive bladder: detection and diagnosis. F1000Res. 2016;5.
Liu S, Chan L, Tse V. Clinical outcome in male patients with detrusor overactivity with impaired contractility. Int Neurourol J. 2014;18(3):133–7.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics FPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.
Goldman HB, Vasavada SP. Female urology: a practical clinical guide. Totowa, NJ: Humana Press Inc.; 2007. p. 7–422.
Lee C-L, Kuo H-C. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Low Urin Tract Symptoms. 2019;11(2):O93–7.
Thiagamoorthy G, Kotes S, Zacchè M, Cardozo L. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. Ther Adv Urol. 2016;8:38–46.
Wang CC, Lee CL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxina injection in patients with detrusor hyperactivity and impaired contractility. Toxins (Basel). 2016;8(3):82.
Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199(1):229–36.
Mehmood S, Altaweel WM. Long-term outcome of sacral neuromodulation in patients with idiopathic nonobstructive urinary retention: single-center experience. Urol Ann. 2017;9(3):244–8.
Hennessey DB, Hoag N, Gani J. Sacral neuromodulation for detrusor hyperactivity with impaired contractility. Neurourol Urodyn. 2017;36(8):2117–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rueb, J.J., Goldman, H.B. (2021). Detrusor Overactivity with Detrusor Underactivity. In: Balzarro, M., Li Marzi, V. (eds) Non-Neurogenic Bladder Dysfunctions. Urodynamics, Neurourology and Pelvic Floor Dysfunctions. Springer, Cham. https://doi.org/10.1007/978-3-030-57393-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-57393-5_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57392-8
Online ISBN: 978-3-030-57393-5
eBook Packages: MedicineMedicine (R0)